Obesity drug VCT220 put to the test: will common meds interfere?
NCT ID NCT07056842
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how two common drugs—rifampin and itraconazole—change the way the body processes VCT220, a new medicine being developed for obesity. Thirty-two healthy adults took VCT220 alone and then with each of these drugs to see if their levels in the blood changed. The goal was to understand potential drug interactions, not to treat obesity directly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Shandong First Medical University
Jinan, Shandong, 250014, China